ENVERIC BIOSCIENCES, INC.
Loading stock data...
Key Financial Metrics (TTM | FY 2024)
-
Revenue
$-9.73M
Net Income
-31.09
EPS (Diluted)
$-14.34M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
$-9.51M
Returns & Efficiency
Return on Assets (ROA)
-223.12%
Return on Equity (ROE)
-281.60%
Gross Profit
-
Operating Income
$-9.75M
Financial Health
Total Assets
$4.36M
Total Debt
-
Debt to Equity
-x
Current Ratio
4.60
Debt Analysis
Debt to EBITDA
-
Debt to Free Cash Flow
-
Cash & Equivalents
-
Net Debt
-
Capital Returns
Return on Invested Capital (ROIC)
-
Invested Capital
-
Stockholders Equity
-
Revenue Growth
-
Market Valuation
Market Cap
-
P/E Ratio
-
Price to Book
-
EPS (Diluted)
$-31.09
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Insider Transactions
Neutral
Open Market Buys: -
Open Market Sales: -
Option Exercise & Sale: -
Net: -
Loading...
Loading insider transactions...
My Notes & Files
Personal Notes
Attached Files
Loading...
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address |
245 FIRST STREET RIVERVIEW II 18TH FLOOR
CAMBRIDGE, MA 02142 |
| Phone | 239-302-1707 |
| Incorporated | DE, US |
| EIN | 954484725 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 313,242.00 |
| Stockholders' Equity | $3.46M |
| Cash & Equivalents | $3.76M |
Recent Filings
View All
424B3
Prospectus (Rule 424b3)
Prospectus filed under Rule 424(b)(3)
Filed: 2026-02-18
Local
EFFECT
Effectiveness Notice
Notice of effectiveness
Filed: 2026-02-17
Local
D
D Filing
SEC regulatory filing
Filed: 2026-02-11
Local
S-1
IPO Registration
Registration statement for initial public offering
Filed: 2026-02-10
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-06
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-02-06
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-14
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-10-27
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-14
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-05-14
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-04-15
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2025-03-28
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2024-12-18
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-11-14
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-08-12
Local
Financial Statistics
Valuation
Market Cap
-
P/E Ratio (TTM)
-
Price to Book
-
EV/Revenue
-
EV/EBITDA
-
Profitability
Gross Margin
-
Operating Margin
-
Net Margin
-
ROE
-281.6%
ROA
-223.1%
Leverage & Liquidity
Debt to Equity
-
Current Ratio
4.60
Total Debt
-
Total Assets
$4.36M
Stockholders' Equity
$3.46M
Income Statement (FY 2024)
Revenue
-
Gross Profit
-
Operating Income
$-9.75M
Net Income
$-9.73M
EPS (Diluted)
$-31.09
Cash Flow (FY 2024)
Free Cash Flow
$-14.34M
Cash & Equivalents
$3.76M
Revenue Growth
-
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...